Filter by:
Muscular Dystrophy
December 2025
European Medical Journal
Breakthroughs in Becker: Unveiling New Natural History Insights and a Novel Agent’s Clinical Progress
Muscular Dystrophy
October 2025
World Muscle Society 2025
LYNX Phase 2 Trial Results in DMD: Positive Effects of Sevasemten, an Investigational Agent, on Physical Function Defines Dose and Informs Design for Phase 3
Muscular Dystrophy
October 2025
World Muscle Society 2025
Trajectory of North Star Ambulatory Assessment with Sevasemten Compares Favorably to Natural History Modeling in Becker Muscular Dystrophy
Muscular Dystrophy
October 2025
World Muscle Society 2025
CANYON Trial Results: Sevasemten, an Investigational Fast Skeletal Myosin Inhibitor, Reduced Muscle Damage Biomarkers and Stabilized Function in BMD
Muscular Dystrophy
October 2025
World Muscle Society 2025
Breakthroughs in Becker: Unveiling New Natural History Insights and a Novel Agent’s Clinical Progress
Muscular Dystrophy
June 2025
European Medical Journal
Understanding Becker Muscular Dystrophy: Disease Overview & Natural History
Muscular Dystrophy
June 2025
Muscle & Nerve
A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy
Muscular Dystrophy
May 2025
European Medical Journal
Spotlight on Becker Muscular Dystrophy: Understanding the Lived Experience of Becker and Clinical Advancements with a Novel Agent
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
